Interferon-alfa- and erythropoetin-associated cerebral vasoconstriction.
Gaillard
N
N
Mania
A
A
Brunel
H
H
Blanc
F
F
Arquizan
C
C
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002560:Cerebrovascular Circulation / Q000187:drug effects; D000068256:Darbepoetin alfa; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D051270:Headache Disorders, Primary / Q000139:chemically induced*; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects*; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D011994:Recombinant Proteins; D014661:Vasoconstriction / Q000187:drug effects
D000998:Antiviral Agents; D006397:Hematinics; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa